Beyond the signaling effect role of amyloid-β42 on the processing of APP, and its clinical implications

Debomoy Lahiri, Bryan Maloney

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Alzheimer's disease (AD) currently has over 6. million victims in the USA, alone. The recently FDA approved drugs for AD only provide mild, transient relief for symptoms without addressing underlying mechanisms to a significant extent. Basic understanding of the activities of the amyloid β peptide (Aβ) and associated proteins such as β-site APP-cleaving enzyme 1 (BACE1) is necessary to develop effective medical responses to AD. Recently (Exper. Neurol. 2010. 221, 18-25), Tabaton et al. have presented a model of both non-pathological and pathological Aβ activities and suggest potential therapeutic pathways based on their proposed framework of Aβ acting as the signal that induces a kinase cascade, ultimately stimulating transcription factors that upregulate genes such as BACE1. We respond by presenting evidence of Aβ's other activities, including protection against metal-induced reactive oxidizing species (ROS), modification of cholesterol transport, and potential activity as a transcription factor in its own right. We touch upon clinical implications of each of these functions and highlight the currently unexplored implications of our suggested novel function of Aβ as a transcription factor. Aβ appears to be a highly multi-functional peptide, and any or all of the pathways it engages in is a likely candidate for antiAD drug development.

Original languageEnglish
Pages (from-to)51-54
Number of pages4
JournalExperimental Neurology
Volume225
Issue number1
DOIs
StatePublished - Sep 2010

Fingerprint

Amyloid
Alzheimer Disease
Transcription Factors
Pharmaceutical Preparations
Phosphotransferases
Up-Regulation
Metals
Cholesterol
Peptides
Enzymes
Genes
Proteins
Therapeutics

Keywords

  • Aging
  • Alzheimer's disease
  • Amyloid beta peptide
  • Clinical trial
  • Dementia
  • Drug discovery
  • Gene regulation
  • Molecular pharmacology
  • Signaling
  • Transcription factor
  • Treatment

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience
  • Medicine(all)

Cite this

Beyond the signaling effect role of amyloid-β42 on the processing of APP, and its clinical implications. / Lahiri, Debomoy; Maloney, Bryan.

In: Experimental Neurology, Vol. 225, No. 1, 09.2010, p. 51-54.

Research output: Contribution to journalArticle

@article{62d496a0ecb3499ebf0ec8c4a4617963,
title = "Beyond the signaling effect role of amyloid-β42 on the processing of APP, and its clinical implications",
abstract = "Alzheimer's disease (AD) currently has over 6. million victims in the USA, alone. The recently FDA approved drugs for AD only provide mild, transient relief for symptoms without addressing underlying mechanisms to a significant extent. Basic understanding of the activities of the amyloid β peptide (Aβ) and associated proteins such as β-site APP-cleaving enzyme 1 (BACE1) is necessary to develop effective medical responses to AD. Recently (Exper. Neurol. 2010. 221, 18-25), Tabaton et al. have presented a model of both non-pathological and pathological Aβ activities and suggest potential therapeutic pathways based on their proposed framework of Aβ acting as the signal that induces a kinase cascade, ultimately stimulating transcription factors that upregulate genes such as BACE1. We respond by presenting evidence of Aβ's other activities, including protection against metal-induced reactive oxidizing species (ROS), modification of cholesterol transport, and potential activity as a transcription factor in its own right. We touch upon clinical implications of each of these functions and highlight the currently unexplored implications of our suggested novel function of Aβ as a transcription factor. Aβ appears to be a highly multi-functional peptide, and any or all of the pathways it engages in is a likely candidate for antiAD drug development.",
keywords = "Aging, Alzheimer's disease, Amyloid beta peptide, Clinical trial, Dementia, Drug discovery, Gene regulation, Molecular pharmacology, Signaling, Transcription factor, Treatment",
author = "Debomoy Lahiri and Bryan Maloney",
year = "2010",
month = "9",
doi = "10.1016/j.expneurol.2010.04.018",
language = "English",
volume = "225",
pages = "51--54",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Beyond the signaling effect role of amyloid-β42 on the processing of APP, and its clinical implications

AU - Lahiri, Debomoy

AU - Maloney, Bryan

PY - 2010/9

Y1 - 2010/9

N2 - Alzheimer's disease (AD) currently has over 6. million victims in the USA, alone. The recently FDA approved drugs for AD only provide mild, transient relief for symptoms without addressing underlying mechanisms to a significant extent. Basic understanding of the activities of the amyloid β peptide (Aβ) and associated proteins such as β-site APP-cleaving enzyme 1 (BACE1) is necessary to develop effective medical responses to AD. Recently (Exper. Neurol. 2010. 221, 18-25), Tabaton et al. have presented a model of both non-pathological and pathological Aβ activities and suggest potential therapeutic pathways based on their proposed framework of Aβ acting as the signal that induces a kinase cascade, ultimately stimulating transcription factors that upregulate genes such as BACE1. We respond by presenting evidence of Aβ's other activities, including protection against metal-induced reactive oxidizing species (ROS), modification of cholesterol transport, and potential activity as a transcription factor in its own right. We touch upon clinical implications of each of these functions and highlight the currently unexplored implications of our suggested novel function of Aβ as a transcription factor. Aβ appears to be a highly multi-functional peptide, and any or all of the pathways it engages in is a likely candidate for antiAD drug development.

AB - Alzheimer's disease (AD) currently has over 6. million victims in the USA, alone. The recently FDA approved drugs for AD only provide mild, transient relief for symptoms without addressing underlying mechanisms to a significant extent. Basic understanding of the activities of the amyloid β peptide (Aβ) and associated proteins such as β-site APP-cleaving enzyme 1 (BACE1) is necessary to develop effective medical responses to AD. Recently (Exper. Neurol. 2010. 221, 18-25), Tabaton et al. have presented a model of both non-pathological and pathological Aβ activities and suggest potential therapeutic pathways based on their proposed framework of Aβ acting as the signal that induces a kinase cascade, ultimately stimulating transcription factors that upregulate genes such as BACE1. We respond by presenting evidence of Aβ's other activities, including protection against metal-induced reactive oxidizing species (ROS), modification of cholesterol transport, and potential activity as a transcription factor in its own right. We touch upon clinical implications of each of these functions and highlight the currently unexplored implications of our suggested novel function of Aβ as a transcription factor. Aβ appears to be a highly multi-functional peptide, and any or all of the pathways it engages in is a likely candidate for antiAD drug development.

KW - Aging

KW - Alzheimer's disease

KW - Amyloid beta peptide

KW - Clinical trial

KW - Dementia

KW - Drug discovery

KW - Gene regulation

KW - Molecular pharmacology

KW - Signaling

KW - Transcription factor

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=77955657566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955657566&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2010.04.018

DO - 10.1016/j.expneurol.2010.04.018

M3 - Article

C2 - 20451519

AN - SCOPUS:77955657566

VL - 225

SP - 51

EP - 54

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 1

ER -